ClearFlow

The page discusses postoperative care and management in cardiac surgery and a subject gaining attention at surgical meetings.

The webinar features Marc Gillinov, MD, Marc Gerdisch, MD, and Alyson Mehringer, RN discussing basic principles of chest tube management.

ClearFlow announced a contract award for products described as improving the healthcare industry.

ClearFlow was selected to exhibit PleuraFlow Active Clearance Technology (ACT), an FDA-cleared chest drainage system.

Significant Reductions in Chest Tube Clogging, Complications, and Resource Use Demonstrated in Prospective Study IRVINE, CA — March 20th, 2025 ClearFlow, Inc.

ClearFlow’s PleuraFlow Active Clearance Technology (ACT) received an Innovative Technology contract from Vizient after hospital experts reviewed it on one of Vizient’s client-led councils.

Paul Molloy participated in two IPOs, led one as CEO in 2005, and exited three of his last four firms as CEO. He serves on the boards of ClearFlow, Inc. and Augustine Medical.

Vizient awards ClearFlow an **Innovative Technology contract** for its **PleuraFlow Active Clearance Technology (ACT)** after a client-driven evaluation highlights its distinct clinical advantages. The contract follows Vizient’s assessment of PleuraFlow’s technology as a differentiated solution in medical drainage systems. ClearFlow’s product targets pleural effusion management, a condition requiring fluid removal from the chest cavity.

Feb 2026ClearFlowNews article

ClearFlow demonstrates its **PleuraFlow ACT** medical device at the **Vizient Innovative Technology Exchange** in Las Vegas. The company was chosen to showcase its technology to healthcare professionals and industry stakeholders. PleuraFlow ACT is designed for pleural effusion management, a condition involving fluid buildup in the lungs.

Sep 2025ClearFlowNews article

ClearFlow’s PleuraFlow device, when integrated into an Enhanced Recovery After Surgery (ERAS) program, reduces complications in cardiac surgery patients. A study of 1,334 patients at Franciscan Health Indianapolis found lower rates of retained blood syndrome, postoperative atrial fibrillation, and shorter ICU stays. The trial highlights the device’s role in improving recovery metrics for cardiac surgery patients.

May 2025ClearFlowNews article

ClearFlow Inc.’s **PleuraFlow ACT** reduces complications in cardiac surgery by lowering retained-blood buildup, chest-tube clogging, and the need for reoperation due to bleeding, according to a randomized trial. The device targets postoperative bleeding risks in high-volume procedures. Results highlight its potential to improve patient outcomes by mitigating common surgical setbacks.

May 2021Medical Product OutsourcingNews article